Back to top
more

Veeva Systems (VEEV)

(Delayed Data from NYSE)

$282.13 USD

282.13
846,410

+2.37 (0.85%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $282.35 +0.22 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alarm Expands Home Automation Portfolio With New Products

by Zacks Equity Research

Alarm (ALRM) recently unveiled Wellcam and Wellness Insights, bolstering its Home Automation Segment and Wellness product line.

Zacks Equity Research

Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.

Zacks Equity Research

Neogen's Canadian Lab Buyout to Boost Genomics Business

by Zacks Equity Research

Neogen (NEOG) continues to adopt initiatives to boost the genomics business.

Zacks Equity Research

LabCorp Rides on Covance Business Amid Reimbursement Woes

by Zacks Equity Research

Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.

Zacks Equity Research

Here's Why Investors Should Hold Luminex (LMNX) Stock Now

by Zacks Equity Research

Luminex (LMNX) gains from strength in the Aries platform. However, cutthroat competition in the life sciences industry is worrisome.

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife

by Zacks Equity Research

AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.

Zacks Equity Research

Omnicell (OMCL) Rides on Innovation Despite Cost Concerns

by Zacks Equity Research

Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.

Zacks Equity Research

Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock for Now

by Zacks Equity Research

A bullish guidance for 2018 and a series of latest developments make Cerner (CERN) a promising investment pick.

Zacks Equity Research

Garmin Certifies Flight Displays, Boosts Aviation Business

by Zacks Equity Research

Garmin (GRMN) announces the certification and availability of G500H TXi touchscreen flight display, in turn bolstering its aviation business.

Zacks Equity Research

Trimble Partners With Neurable, Brings BCI to AEC Customers

by Zacks Equity Research

Trimble (TRMB) partners with Neurable to enhance customer safety by bringing BCI technology for application in real world.

Zacks Equity Research

LMNX or PACB: Which is a Better MedTech Investment Pick?

by Zacks Equity Research

Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.

Zacks Equity Research

LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite

by Zacks Equity Research

LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.

Zacks Equity Research

Here's Why You Should Add CVS Health to Your Portfolio Now

by Zacks Equity Research

CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.

Zacks Equity Research

Cerner (CERN) Collaborates With McKesson's CoverMyMeds

by Zacks Equity Research

Cerner's (CERN) ePrescribe workflow solution is likely to partner with CoverMyMeds' RxBenefit Clarity solution for prescription price transparency.

Zacks Equity Research

Apple (AAPL) Slashes Sales Forecast for Q1, Blames China

by Zacks Equity Research

Apple (AAPL) slashes its quarterly revenue forecasts for the first-quarter fiscal 2019, blaming decelerating growth in China.

Zacks Equity Research

Luminex Buys MilliporeSigma's Flow Cytometry Unit for $75M

by Zacks Equity Research

The recent buyout is likely to contribute $40-$50 million to Luminex's (LMNX) revenues in 2019.

Zacks Equity Research

Solid Global Business Aids NuVasive Amid Pricing Pressure

by Zacks Equity Research

Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.

Zacks Equity Research

Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

by Zacks Equity Research

Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

by Zacks Equity Research

A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.

Zacks Equity Research

Cardiovascular Systems Gets Approvals in Japan, Widens Suite

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.

Zacks Equity Research

Here's Why You Should Invest in Wright Medical (WMGI) Now

by Zacks Equity Research

A bullish outlook and a wide array of products make Wright Medical (WMGI) a promising investment pick.

Zacks Equity Research

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.

Zacks Equity Research

Walgreens Counts on International Progress, Strategic Deals

by Zacks Equity Research

We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.

Zacks Equity Research

Cardiovascular Systems Treats First Patient With Teleport

by Zacks Equity Research

Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.